Exome Asset Management’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
Exome Asset Management's NKTR Position: Q3 2026 in Review
Exome Asset Management increased its Nektar Therapeutics (NKTR) stake by 229% in Q3 2026, buying an estimated $3.6M and bringing the position to 73,708 shares worth $4.46M. The position accounts for 2.92% of the portfolio, ranked #13.
Exome Asset Management first reported a position in NKTR in Q4 2024 and has held it in 4 quarters since. 242 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.
- Exome Asset Management held 73,708 shares of Nektar Therapeutics worth $4.46M as of Q3 2026.
- Exome Asset Management bought 51,291 Nektar Therapeutics shares in Q3 2026, an estimated $3.6M.
- Nektar Therapeutics made up 2.92% of Exome Asset Management's portfolio in Q3 2026, its #13 holding.
- Exome Asset Management first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 4 quarters since.
- 242 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.
Based on Exome Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.